Text Size

Quercetin in Children With Fanconi Anemia; a Pilot Study

This study is currently recruiting participants.
Verified October 2012 by Children's Hospital Medical Center, Cincinnati
Sponsor:
Information provided by (Responsible Party):
Children's Hospital Medical Center, Cincinnati
ClinicalTrials.gov Identifier:
NCT01720147
First received: July 25, 2012
Last updated: October 31, 2012
Last verified: October 2012
History of Changes
  Purpose

Fanconi anemia (FA) is an autosomal recessive disease characterized by progressive bone marrow failure (BMF), congenital abnormalities and a predisposition to malignancy. Current therapies for children with Fanconi anemia (FA) and bone marrow failure, i.e. androgens or bone marrow transplantation, are associated with significant morbidity and mortality.

This is a pilot study aiming to assess feasibility, toxicity and pharmacokinetics of oral Quercetin therapy in patients with FA. This is a first step towards a clinical study of the efficacy of Quercetin therapy in delaying progression of BMF in FA.

Additional correlative studies will include assessment of impact of Quercetin on reduction of Reactive Oxygen Species (ROS), maintenance or improvement of hematopoietic stem cell (HSC) reserve, improvement of hematopoiesis (i.e. peripheral counts) and insulin sensitivity/glucose tolerance.

This study is an open-label single arm study.


Condition Intervention Phase
Fanconi Anemia
 Drug: Quercetin (dietary supplement)
 Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Quercetin in Children With Fanconi Anemia; a Pilot Study

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Children's Hospital Medical Center, Cincinnati:

Primary Outcome Measures:
  • Measure the ability to administer twice daily oral quercetin therapy in patients with Fanconi Anemia (FA). [ Time Frame: 4 months (16 weeks) ] [ Designated as safety issue: Yes ]
  • Measure safety of oral quercetin therapy in patients with FA [ Time Frame: 4 months (16 weeks) ] [ Designated as safety issue: Yes ]
  • To measure pharmacokinetics (PK) of oral quercetin therapy in patients with FA [ Time Frame: 4 months (16 weeks) ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To measure the impact of quercetin therapy on reduction of Reactive Oxygen Species (ROS). [ Time Frame: 4 months (16 weeks) and 1 year ] [ Designated as safety issue: Yes ]
  • Number of participants with improved hematopoiesis. [ Time Frame: 4 months (16 weeks) and 1 year ] [ Designated as safety issue: Yes ]
  • Measure the preservation of hematopoietic stem cell reserve in patients with FA [ Time Frame: 4 months (16 weeks) and 1 year ] [ Designated as safety issue: Yes ]
  • Number of participants with changes in insulin sensitivity/glucose tolerance. [ Time Frame: 4 month (16 weeks) and 1 year ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 12
Study Start Date: July 2012
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Quercetin (dietary supplement)
    Quercetin will be given orally on a twice a day schedule starting with weight adjusted dose for a maximum total daily dose of 750 mg/day in the first 3 patients to potentially increase up to a maximum dose of 1500 mg/day, for 4 months (16 weeks). If any of the patients in the first cohort is 70 kg or more, the starting dose will be automatically assigned at the maximum dose of 750 mg/day. Pharmacokinetics (PK) data will be used to optimize the dosing schedule(if required)for subsequent patients.
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of FA proven by DEB test
  • Able to take enteral medication

Exclusion Criteria:

  • Patients with morphological evidence of myelodysplasia or leukemia
  • Renal failure requiring dialysis
  • Total bilirubin > 3 mg/dl and/or SGPT >200 at time of enrollment
  • Patients who are pregnant or breastfeeding or are at risk of pregnancy and are unable to use acceptable methods of birth control during the length of the study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01720147

Contacts
Contact: Stephanie Edwards, BSN 513-636-9292 stephanieL.edwards@cchmc.org
Contact: Jamie Wilhelm 513-803-1102 jamie.wilhelm@cchmc.org

Locations
United States, Ohio
Cincinnati Children's Hospital Medical Center Recruiting
Cincinnati, Ohio, United States, 45229
Principal Investigator: Parinda Mehta, MD            
Sponsors and Collaborators
Children's Hospital Medical Center, Cincinnati
Investigators
Principal Investigator: Parinda Mehta, MD Children's Hospital Medical Center, Cincinnati
  More Information

No publications provided

Responsible Party: Children's Hospital Medical Center, Cincinnati
ClinicalTrials.gov Identifier: NCT01720147     History of Changes
Other Study ID Numbers: 2011-2049
Study First Received: July 25, 2012
Last Updated: October 31, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Children's Hospital Medical Center, Cincinnati:
Fanconi Anemia
FA
Quercetin

Additional relevant MeSH terms:
Anemia
Fanconi Anemia
Fanconi Syndrome
Hematologic Diseases
Anemia, Hypoplastic, Congenital
Anemia, Aplastic
Bone Marrow Diseases
Genetic Diseases, Inborn
DNA Repair-Deficiency Disorders
Metabolic Diseases
 Kidney Diseases
Urologic Diseases
Renal Tubular Transport, Inborn Errors
Metabolism, Inborn Errors
Quercetin
Antioxidants
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protective Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 23, 2013